CLYM: Climb Bio Inc Growth-Adjusted Market Cap to Net Income
Climb Bio Inc (CLYM) focuses on developing immunotherapies, which creates binary risks due to the absence of sales. The PEG ratio trajectory demonstrates local dynamics, where the value of 0.00 serves as the baseline valuation metric. High R&D costs and patents limit competitor entry. Meanwhile, a unique drug for the treatment of lupus provides the company with significant pricing power amid inelastic demand.
Metric breakdowns and analytics for Climb Bio Inc (CLYM)
- share price and consensus valuation forecast:
- market capitalization information:
- company book value details:
- issuer credit burden and liquidity indicators:
- business earnings and investment ratios data:
CLYM - Net Profit|Company Profit Forecast Climb Bio Inc|CLYM - Price to Earnings Ratio|Projected Price to Earnings Climb Bio, Inc|CLYM - PEG Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Climb Bio Inc|CLYM - Operating profit before deduction of amortization|Earnings per share for the trailing year Climb Bio|CLYM - Net earnings per share (EPS TTM)|Year-over-year earnings per share growth for the last twelve months climbbio.com|CLYM - Earnings growth in current year|Consensus forecast of earnings per share growth for next year Climb Bio Inc
General company analysis:CLYM - Climb Bio Inc.
This indicator correlates the market value of earnings with their growth rate, where a value below one signals that the asset is undervalued relative to its expansion. By analyzing the PEG ratio, a Climb Bio Inc (CLYM) investor can balance the risk of high R&D expenditures on immunological molecules with capitalization potential, while assessing the efficiency of the existing cash reserve utilization.
Competing companies
ARGX (argenx N.V.) - Growth-Adjusted Payback Ratio|PEG Multiple BNTX (BioNTech Group)|Growth-Adjusted Market Cap to Net Income Abivax (ABVX)|ADMA - Price/Earnings to Growth Ratio|protagonist-inc.com (PTGX) - Price/Earnings to Growth Multiple|Immunovant (IMVT) - Price/Earnings to Growth Ratio|Price/Earnings to Growth Multiple Kiniksa Pharmaceuticals, Ltd.|Price/Earnings to Growth Multiple GRFS|PEG Multiple Adaptive Biotechnologies Inc.|Price/Earnings to Growth Ratio Celldex Therapeutics (CLDX)|auriniapharma.com - Growth-Adjusted P/E Ratio|PEG Multiple BCRX (BioCryst Pharmaceuticals)|Vera Therapeutics Inc (VERA) - Price to Earnings Adjusted for Growth Rate|Dianthus Pharma - PEG Multiple|Pharvaris Pharma (PHVS) - Price/Earnings to Growth Multiple|abcellera.com (ABCL) - Price/Earnings to Growth Ratio|TRML (tourmalinebio.com) - Price/Earnings to Growth Ratio|PGEN (Precigen) - PEG Multiple|Pharming Group NV (PHAR) - Growth-Adjusted Market Cap to Net Income|Price/Earnings to Growth Ratio Nektar (NKTR)|Price/Earnings to Growth Multiple Upstream Pharma UPB|PEG Multiple ZBIO (Zenas Biopharma Inc)|immunome.com - Price/Earnings to Growth Ratio|GOSS: Price/Earnings to Growth Multiple|Growth-Adjusted Payback Ratio KALV (KalVista Pharma)|SEPN: PEG Multiple|PVLA (Pieris Corp) - Price/Earnings to Growth Ratio|SVRA (Savara Inc.) - PEG Multiple|rigel.com (RIGL) - Growth-Adjusted Market Cap to Net Income|Price/Earnings to Growth Ratio AnaptysBio (ANAB)|ATXS - Price to Earnings Adjusted for Growth Rate|enGene Bio - Price/Earnings to Growth Multiple|Growth-Adjusted Payback Ratio RAPT|Aerovate - PEG Multiple|Growth-Adjusted Market Cap to Net Income aclaristx.com ACRS|Kyverna Therapeutics, Inc. (KYTX) - Price/Earnings to Growth Ratio|Growth-Adjusted P/E Ratio TLSA|CABA (Cabaletta Bio, Inc) - PEG Multiple|Price/Earnings to Growth Multiple Ventyx Biosciences, Inc (VTYX)|PEG Multiple THTX|Price/Earnings to Growth Multiple avalotx.com AVTX|Price/Earnings to Growth Ratio Eledon Pharmaceuticals, Inc. ELDN|Agenus, Inc. - Price/Earnings to Growth Ratio|ZURA: Price/Earnings to Growth Multiple|Price to Earnings Adjusted for Growth Rate aTyr Pharmaceuticals|adagene.com (ADAG) - Price/Earnings to Growth Ratio|Price/Earnings to Growth Multiple Ikena Oncology|Price/Earnings to Growth Ratio Shattuck Labs Inc|Equillium Bio - Market Cap to Earnings and Growth Ratio|PEG Multiple CNTB|IMUX (immunic-therapeutics.com) - Growth-Adjusted Payback Ratio|PEG Multiple ATRA (Atara Bio)|PEG Multiple InflaRx NV IFRX|XFOR - Price/Earnings to Growth Ratio|Growth-Adjusted Payback Ratio ACET (Adicet Bio)|celularity.com (CELU) - Price/Earnings to Growth Ratio|Price/Earnings to Growth Multiple INmune Bio Corporation|BRNS (Barinthus Biotherapeutics) - PEG Multiple|PEG Multiple kezarlifesciences.com|Price/Earnings to Growth Multiple SABS (SAB Biotherapeutics, Inc.)|AKTX (Akari Therapeutics PLC) - Growth-Adjusted Payback Ratio|PEG Multiple ENLV (Enlivex Therapeutics Ltd.)|Growth-Adjusted Market Cap to Net Income Q32 Bio Inc (QTTB)|GOVX - Price/Earnings to Growth Ratio|edesabiotech.com (EDSA) - Price/Earnings to Growth Multiple|iBio (IBIO) - Price/Earnings to Growth Ratio|Price/Earnings to Growth Multiple Carisma Therapeutics Inc.|Price/Earnings to Growth Multiple XTLB|PEG Multiple Bolt Bio|Price/Earnings to Growth Ratio HCW Biologics Inc. (HCWB)|aptevotherapeutics.com - Growth-Adjusted P/E Ratio|PEG Multiple AIM (AIM ImmunoTech)|Aditxt Inc. (ADTX) - Price to Earnings Adjusted for Growth Rate|GRI Bio Corp - PEG Multiple|XORTX Corp (XRTX) - Price/Earnings to Growth Multiple|Vyome Holdings Inc (HIND) - Price/Earnings to Growth Ratio|REVB (revbiosciences.com) - Price/Earnings to Growth Ratio|INDP (Indaptus Therapeutics, Inc.) - PEG Multiple|Scinai Immunotherapeutics Ltd (SCNI) - Growth-Adjusted Market Cap to Net Income|Price/Earnings to Growth Ratio CalciMedica, Inc. (CALI)|Price/Earnings to Growth Multiple affimed.com AFMD|PEG Multiple ALLK (Allakos)|HOOKIPA Pharma, Inc. - Price/Earnings to Growth Ratio|IGMS: Price/Earnings to Growth Multiple|Growth-Adjusted Payback Ratio ITOS (iTeos Therapeutics Inc)|OCEA: PEG Multiple|TCBP (TC BioPharm Ltd) - Price/Earnings to Growth Ratio|THRD (Third Harmonic Bio) - PEG Multiple
